Answers are grounded in this paper and cite their sources.
Genomic alterations and targeted therapy response were observed in NSCLC patients, indicating critical insights for personalized treatment strategies.
Keywords: EGFR, genomic alterations, non-small cell lung cancer, targeted therapy, KRAS Citation: Deng L, Li J, Qiu Z and Wang Y (2026) Correction: Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics. Front. Genet. 17:1794164. doi: 10.3389/fgene.2026.1794164 Received: 22 January 2026; Accepted: 23 January 2026; Published: 30 January 2026. Approved by: Copyright © 2026 Deng, Li, Qiu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Yanfen Wang, 2022695043@gzhmu.edu.cn
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: